Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Phase 2
Recruiting
- Conditions
- Malignant Peritoneal Mesothelioma, Advanced
- Interventions
- Drug: Sintilimab, Bevacizumab , Pemetrexed , Cisplatin
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 28
- Registration Number
- NCT06543069
- Locations
- 🇨🇳
Cancer Institute and Hospital,Chinese Academy of Medical Sciences, Beijing, China
A Study of ES014 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 15
- Registration Number
- NCT06543056
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 50
- Registration Number
- NCT06540937
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2024-08-06
- Last Posted Date
- 2024-08-06
- Target Recruit Count
- 30
- Registration Number
- NCT06540508
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Target Recruit Count
- 9
- Registration Number
- NCT06509490
- Locations
- 🇨🇳
Cancer hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Goal-directed Enteral Nutritional Perioperative Management
Not Applicable
Recruiting
- Conditions
- Esophagus Cancer
- Interventions
- Dietary Supplement: Goal-directed EN therapyDietary Supplement: Conventional EN therapy
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Target Recruit Count
- 400
- Registration Number
- NCT06510543
- Locations
- 🇨🇳
Shandong Provincial Hospital, Jinan, Shandong, China
🇨🇳Changzhi People's Hospital, Changzhi, Shanxi, China
🇨🇳Shanxi Cancer Hospital, Chinese Academy of Medical Sciences, Taiyuan, Shanxi, China
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Nasopharyngeal Carcinoma by AJCC V8 Stage
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Target Recruit Count
- 30
- Registration Number
- NCT06509009
Longitudinal Study on the Evolution Trend and Influencing Factors of Postoperative Reflux of Esophageal Cancer Based on PEPTEST Technique
- Conditions
- GASTROINTESTINAL NEOPLASMS
- Interventions
- Diagnostic Test: PEPTEST test
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Target Recruit Count
- 138
- Registration Number
- NCT06509022
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy
Phase 2
Not yet recruiting
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Target Recruit Count
- 9
- Registration Number
- NCT06501976
MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer
Phase 2
Recruiting
- Conditions
- Esophageal Cancer
- Interventions
- Drug: PD-1 monoclonal antibody consolidation therapy
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-08-06
- Target Recruit Count
- 102
- Registration Number
- NCT06498752
- Locations
- 🇨🇳
Cancer hospital, CAMS, Beijing, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath